Duffin Kathleen, Mitchell Rod T, Brougham Mark F H, Hamer Geert, van Pelt Ans M M, Mulder Callista L
Department of Biomedical Sciences, University of Edinburgh, George Square, Edinburgh, EH8 9XD, UK; Royal Hospital for Children and Young People, 50 Little France Crescent, Edinburgh, EH16 4TJ, UK.
Royal Hospital for Children and Young People, 50 Little France Crescent, Edinburgh, EH16 4TJ, UK; Centre for Reproductive Health, Institute of Regeneration and Repair, University of Edinburgh, 4-5 Little France Drive, Edinburgh BioQuarter, Edinburgh, EH16 4UU, UK.
Mol Aspects Med. 2024 Dec;100:101308. doi: 10.1016/j.mam.2024.101308. Epub 2024 Sep 11.
Over the past two decades, advances in cancer therapy have significantly improved survival rates, particularly in childhood cancers. Still, many treatments pose a substantial risk for diminishing future fertility potential due to the gonadotoxic nature of many cancer regimens, justifying fertility preservation programs for both childhood and adult cancer patients. To assure a balance between offering fertility preservation and actual chance of infertility post-treatment, guidelines are in place. However, assessing the actual risk of infertility after treatment remains challenging, given the multi-faceted approach of many cancer treatment plans, which are continuously evolving. This review discusses the evolution of cancer therapy over the past 20 years and attempts to assess their impact on fertility after treatment. Overall, cancer regimens have shifted from broadly killing fast dividing cells to more targeting therapies, reducing collateral damage in general. Although progress has been made to reduce overall toxicity, unfortunately this does not automatically translate to reduced gonadotoxicity. Therefore, current fertility preservation programs continue to be an important part of cancer care.
在过去二十年中,癌症治疗的进展显著提高了生存率,尤其是在儿童癌症方面。然而,由于许多癌症治疗方案具有性腺毒性,许多治疗方法对未来生育潜力的降低构成了重大风险,这使得为儿童和成年癌症患者开展生育力保存计划具有合理性。为了确保在提供生育力保存和治疗后实际不孕几率之间取得平衡,相关指南已经出台。然而,鉴于许多癌症治疗方案的多方面性质且这些方案在不断演变,评估治疗后实际的不孕风险仍然具有挑战性。本综述讨论了过去20年癌症治疗的演变,并试图评估其对治疗后生育力的影响。总体而言,癌症治疗方案已从广泛杀死快速分裂细胞转向更多的靶向治疗,总体上减少了附带损害。尽管在降低总体毒性方面取得了进展,但不幸的是,这并不自动转化为性腺毒性的降低。因此,当前的生育力保存计划仍然是癌症治疗的重要组成部分。